There are 2949 resources available
566P - A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours
Presenter: Michael Carducci
Session: E-Poster Display
Resources:
Abstract
567P - Exposure-response analyses of dabrafenib and trametinib in melanoma patients
Presenter: Steffie Groenland
Session: E-Poster Display
Resources:
Abstract
568P - Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
Presenter: Ilaria Colombo
Session: E-Poster Display
Resources:
Abstract
569P - Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce complete tumour responses and anti-tumour immune memory in a mouse tumour model
Presenter: Alex Karlsson-Parra
Session: E-Poster Display
Resources:
Abstract
570P - A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC
Presenter: Makoto Nishio
Session: E-Poster Display
Resources:
Abstract
571P - Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)
Presenter: Dirk Zboralski
Session: E-Poster Display
Resources:
Abstract
572P - Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials
Presenter: Omar Saavedra Santa Gadea
Session: E-Poster Display
Resources:
Abstract
573P - Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure
Presenter: Alberto Hernando-Calvo
Session: E-Poster Display
Resources:
Abstract
574P - Updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours
Presenter: Paul de Souza
Session: E-Poster Display
Resources:
Abstract
575P - TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16)
Presenter: Dagmar Hess
Session: E-Poster Display
Resources:
Abstract